Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Voyager Therapeutics (VYGR – Research Report). The associated price target remains the same with $9.00.
Yun Zhong’s rating is based on the promising results from Voyager Therapeutics’ recent Phase 1 study of their anti-tau antibody, VY7523. The study demonstrated that VY7523 is safe and well-tolerated in healthy volunteers, with favorable pharmacokinetics and adequate penetration into the central nervous system. Additionally, the initiation of a Phase 2 study in patients with early Alzheimer’s disease signifies a strategic step forward, with future data expected to provide insights into the antibody’s efficacy in preventing tau spread.
Preclinical data further support VY7523’s potential, showing a significant reduction in pathological tau spreading in animal models. This is particularly encouraging given the challenges faced by other antibodies targeting different tau epitopes. The broader landscape of anti-tau antibody research, with several companies advancing similar programs, also suggests potential catalysts for Voyager Therapeutics as the field progresses. These factors collectively underpin Yun Zhong’s Buy rating for Voyager Therapeutics.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $30.00 price target.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year.